Jessica G Shantha1, Ian Crozier2, Brent R Hayek1, Beau B Bruce3, Catherine Gargu4, Jerry Brown5, John Fankhauser5, Steven Yeh6. 1. Department of Ophthalmology, Emory Eye Center, Emory University School of Medicine, Atlanta, Georgia. 2. Infectious Diseases Institute, Kampala, Uganda. 3. Department of Ophthalmology, Emory Eye Center, Emory University School of Medicine, Atlanta, Georgia; Department of Neurology, Emory University School of Medicine, Atlanta, Georgia; Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia. 4. Ministry of Health and Sanitation, Monrovia, Liberia. 5. Eternal Love Winning Africa Hospital, Monrovia, Liberia. 6. Department of Ophthalmology, Emory Eye Center, Emory University School of Medicine, Atlanta, Georgia. Electronic address: steven.yeh@emory.edu.
Abstract
PURPOSE: To describe the ocular findings, visual impairment, and association of structural complications of uveitis with visual impairment in a cohort of survivors of Ebola virus disease (EVD) in Monrovia, Liberia. DESIGN: Retrospective, uncontrolled, cross-sectional study. PARTICIPANTS: Survivors of EVD who were evaluated in an ophthalmology clinic at Eternal Love Winning Africa (ELWA) Hospital in Monrovia, Liberia. METHODS: A cohort of EVD survivors who underwent baseline ophthalmic evaluation at ELWA Hospital were retrospectively reviewed for demographic information, length of Ebola treatment unit (ETU) stay, visual acuity (VA), and ophthalmic examination findings. For patients with uveitis, disease activity (active vs. inactive) and grade of inflammation were recorded according to Standardization of Uveitis Nomenclature criteria. The level of VA impairment was categorized according to World Health Organization classification for VA impairment as follows: normal/mild, VA 20/70 or better; moderate, VA 20/70-20/200; severe, VA 20/200-20/400; blindness, VA <20/400. Visual acuity, length of ETU stay, and structural complications were compared between EVD survivors with and without uveitis. Structural complications associated with moderate VA impairment or poorer were analyzed. MAIN OUTCOME MEASURES: Frequency of ocular complications including uveitis and optic neuropathy in EVD survivors, level of VA impairment in EVD survivors with uveitis, and structural complications associated with VA impairment in EVD survivors. RESULTS: A total of 96 survivors of EVD were examined. A total of 21 patients developed an EVD-associated uveitis, and 3 patients developed an EVD-associated optic neuropathy. Visual acuity was blind (VA >20/400) in 38.5% of eyes with uveitis. Anatomic subtypes of uveitis included anterior, posterior, and panuveitis in 2, 13, and 6 patients, respectively. Examination findings associated with at least moderate visual impairment by World Health Organization criteria (VA <20/70) included keratic precipitates (P < 0.002), posterior synechiae (P < 0.002), vitritis (P < 0.005), and chorioretinal scars (P < 0.02). CONCLUSIONS: Survivors of EVD are at risk for uveitis, which may lead to secondary structural complications, visual impairment, and blindness. Eye care resources should be mobilized for EVD survivors in West Africa because of the frequency of this spectrum of disease complication and its potential for severe VA impairment and blindness.
PURPOSE: To describe the ocular findings, visual impairment, and association of structural complications of uveitis with visual impairment in a cohort of survivors of Ebola virus disease (EVD) in Monrovia, Liberia. DESIGN: Retrospective, uncontrolled, cross-sectional study. PARTICIPANTS: Survivors of EVD who were evaluated in an ophthalmology clinic at Eternal Love Winning Africa (ELWA) Hospital in Monrovia, Liberia. METHODS: A cohort of EVD survivors who underwent baseline ophthalmic evaluation at ELWA Hospital were retrospectively reviewed for demographic information, length of Ebola treatment unit (ETU) stay, visual acuity (VA), and ophthalmic examination findings. For patients with uveitis, disease activity (active vs. inactive) and grade of inflammation were recorded according to Standardization of Uveitis Nomenclature criteria. The level of VA impairment was categorized according to World Health Organization classification for VA impairment as follows: normal/mild, VA 20/70 or better; moderate, VA 20/70-20/200; severe, VA 20/200-20/400; blindness, VA <20/400. Visual acuity, length of ETU stay, and structural complications were compared between EVD survivors with and without uveitis. Structural complications associated with moderate VA impairment or poorer were analyzed. MAIN OUTCOME MEASURES: Frequency of ocular complications including uveitis and optic neuropathy in EVD survivors, level of VA impairment in EVD survivors with uveitis, and structural complications associated with VA impairment in EVD survivors. RESULTS: A total of 96 survivors of EVD were examined. A total of 21 patients developed an EVD-associated uveitis, and 3 patients developed an EVD-associated optic neuropathy. Visual acuity was blind (VA >20/400) in 38.5% of eyes with uveitis. Anatomic subtypes of uveitis included anterior, posterior, and panuveitis in 2, 13, and 6 patients, respectively. Examination findings associated with at least moderate visual impairment by World Health Organization criteria (VA <20/70) included keratic precipitates (P < 0.002), posterior synechiae (P < 0.002), vitritis (P < 0.005), and chorioretinal scars (P < 0.02). CONCLUSIONS: Survivors of EVD are at risk for uveitis, which may lead to secondary structural complications, visual impairment, and blindness. Eye care resources should be mobilized for EVD survivors in West Africa because of the frequency of this spectrum of disease complication and its potential for severe VA impairment and blindness.
Authors: Jay B Varkey; Jessica G Shantha; Ian Crozier; Colleen S Kraft; G Marshall Lyon; Aneesh K Mehta; Gokul Kumar; Justine R Smith; Markus H Kainulainen; Shannon Whitmer; Ute Ströher; Timothy M Uyeki; Bruce S Ribner; Steven Yeh Journal: N Engl J Med Date: 2015-05-07 Impact factor: 91.245
Authors: Danielle V Clark; Hannah Kibuuka; Monica Millard; Salim Wakabi; Luswa Lukwago; Alison Taylor; Michael A Eller; Leigh Anne Eller; Nelson L Michael; Anna N Honko; Gene G Olinger; Randal J Schoepp; Matthew J Hepburn; Lisa E Hensley; Merlin L Robb Journal: Lancet Infect Dis Date: 2015-04-21 Impact factor: 25.071
Authors: K Kibadi; K Mupapa; K Kuvula; M Massamba; D Ndaberey; J J Muyembe-Tamfum; M A Bwaka; A De Roo; R Colebunders Journal: J Infect Dis Date: 1999-02 Impact factor: 5.226
Authors: Daniel S Chertow; Avindra Nath; Anthony F Suffredini; Robert L Danner; Daniel S Reich; Rachel J Bishop; Richard W Childs; Andrew E Arai; Tara N Palmore; H Clifford Lane; Anthony S Fauci; Richard T Davey Journal: Ann Intern Med Date: 2016-04-05 Impact factor: 25.391
Authors: John G Mattia; Mathew J Vandy; Joyce C Chang; Devin E Platt; Kerry Dierberg; Daniel G Bausch; Tim Brooks; Sampha Conteh; Ian Crozier; Robert A Fowler; Amadu P Kamara; Cindy Kang; Srividya Mahadevan; Yealie Mansaray; Lauren Marcell; Gillian McKay; Tim O'Dempsey; Victoria Parris; Ruxandra Pinto; Audrey Rangel; Alex P Salam; Jessica Shantha; Vanessa Wolfman; Steven Yeh; Adrienne K Chan; Sharmistha Mishra Journal: Lancet Infect Dis Date: 2015-12-23 Impact factor: 25.071
Authors: Janet T Scott; Foday R Sesay; Thomas A Massaquoi; Baimba R Idriss; Foday Sahr; Malcolm G Semple Journal: Emerg Infect Dis Date: 2016-04 Impact factor: 6.883
Authors: John R Chancellor; Sriranjani P Padmanabhan; Thomas C Greenough; Richard Sacra; Richard T Ellison; Lawrence C Madoff; Rebecca J Droms; David M Hinkle; George K Asdourian; Robert W Finberg; Ute Stroher; Timothy M Uyeki; Olga M Cerón Journal: Emerg Infect Dis Date: 2016-02 Impact factor: 6.883
Authors: Michael C Sneller; Cavan Reilly; Moses Badio; Rachel J Bishop; Allen O Eghrari; Soka J Moses; Kumblytee L Johnson; Dehkontee Gayedyu-Dennis; Lisa E Hensley; Elizabeth S Higgs; Avindra Nath; Kaylie Tuznik; Justin Varughese; Kenneth S Jensen; Bonnie Dighero-Kemp; James D Neaton; H Clifford Lane; Mosoka P Fallah Journal: N Engl J Med Date: 2019-03-07 Impact factor: 91.245
Authors: Shevin T Jacob; Ian Crozier; William A Fischer; Angela Hewlett; Colleen S Kraft; Marc-Antoine de La Vega; Moses J Soka; Victoria Wahl; Anthony Griffiths; Laura Bollinger; Jens H Kuhn Journal: Nat Rev Dis Primers Date: 2020-02-20 Impact factor: 52.329
Authors: Paul J Steptoe; Janet T Scott; Julia M Baxter; Craig K Parkes; Rahul Dwivedi; Gabriela Czanner; Matthew J Vandy; Fayiah Momorie; Alimamy D Fornah; Patrick Komba; Jade Richards; Foday Sahr; Nicholas A V Beare; Malcolm G Semple Journal: Emerg Infect Dis Date: 2017-07 Impact factor: 6.883
Authors: Justine R Smith; Shawn Todd; Liam M Ashander; Theodosia Charitou; Yuefang Ma; Steven Yeh; Ian Crozier; Michael Z Michael; Binoy Appukuttan; Keryn A Williams; David J Lynn; Glenn A Marsh Journal: Transl Vis Sci Technol Date: 2017-07-14 Impact factor: 3.283